{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:42:52Z","timestamp":1792806172922,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Incyte Biosciences Iberia S.L."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Biliary tract cancer (BTC), which includes cholangiocarcinoma (CCA) and gallbladder cancer (GBC), presents high levels of molecular heterogeneity and a poor prognosis. Next-generation sequencing (NGS) is crucial for identifying genomic alterations and adequate targeted therapies, but its integration into clinical practice varies by region. This study assesses how NGS is implemented in Spain, focusing on its use, barriers, and clinical impact on managing BTC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was based on a national survey of healthcare professionals involved in the diagnosis and treatment of BTC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-six experts participated in the general analysis, and 58 participated in the BTC-specific analysis. Among the respondents, 95% reported access to NGS in oncology practice, and 93% reported its use in BTC. FGFR2 and IDH1\/2 were the most frequently requested biomarkers (both 91%), whereas TMB (22%) and expanded panels were less commonly used. Thirty-two of 50 respondents requested NGS in advanced disease (64%), as per the responses to this specific question, which is consistent with current therapeutic indications. Thirty-four of 48 respondents performing NGS (71%) reported access to specialized genetic counseling. The perceived therapeutic impact varied: many estimated that NGS influenced treatment decisions in 20\u201340% of cases, whereas a subset reported that it influenced treatment decisions in more than 60% of cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The adoption of NGS in BTC management in Spain has increased alongside the availability of targeted therapies. The respondents reported broad access to NGS and frequent use of key biomarkers, mainly in advanced disease. Variability in biomarker selection, timing, and access to counseling reflects differences in local practice. Initiatives that support harmonized diagnostic pathways may further strengthen precision oncology in BTC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12094-026-04397-3","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T13:19:33Z","timestamp":1779974373000},"page":"5344-5354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current patterns of next-generation sequencing testing in biliary tract cancer patients in Spain"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3959-4120","authenticated-orcid":false,"given":"Jorge","family":"Adeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Carrato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Macarulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD Group)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"4397_CR1","doi-asserted-by":"crossref","unstructured":"Kratz ,JD Klein, AB Gray, CB, Mrten, A Vilu, HL Knight, JF Kumichel, A Ueno M. The Epidemiology of Biliary Tract Cancer and Associated Prevalence of MDM2 Amplification: A Targeted Literature Review. 2024; Available from: https:\/\/europepmc.org\/article\/MED\/39302603","DOI":"10.1007\/s11523-024-01086-5"},{"key":"4397_CR2","doi-asserted-by":"crossref","unstructured":"Hussain, MM Wang, JM, Zhai, AQ Li, FY Hu H. Comparison of prognostic factors and their differences in intrahepatic, hilar, and distal cholangiocarcinoma: A systematic review and meta-analysis. 2025; Available from: https:\/\/europepmc.org\/article\/MED\/40697248","DOI":"10.4251\/wjgo.v17.i7.107995"},{"key":"4397_CR3","doi-asserted-by":"crossref","unstructured":"Chaudhary U SSL. Advances in Endoscopic Diagnosis and Management of Cholangiocarcinoma. 2025; Available from: https:\/\/europepmc.org\/article\/MED\/40943794","DOI":"10.3390\/jcm14176028"},{"key":"4397_CR4","doi-asserted-by":"crossref","unstructured":"Woo S Kim Y, Hwang, S Chon H. Epidemiology and genomic features of biliary tract cancer and its unique features in Korea. J Liver Cancer. 2025; Available from: https:\/\/europepmc.org\/article\/MED\/40033637","DOI":"10.17998\/jlc.2025.02.27"},{"key":"4397_CR5","doi-asserted-by":"publisher","DOI":"10.20517\/2394-5079.2021.130","volume":"8","author":"F Turati","year":"2022","unstructured":"Turati F, Bertuccio P, Negri E, La Vecchia C. Epidemiology of cholangiocarcinoma. Hepatoma Res. 2022;8:19. https:\/\/doi.org\/10.20517\/2394-5079.2021.130.","journal-title":"Hepatoma Res"},{"key":"4397_CR6","unstructured":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica (SEOM). C\u00e1ncer de v\u00eda biliar. Epidemiolog\u00eda. 2025 [cited 2025 Nov 13]. Available from: https:\/\/seom.org\/info-sobre-el-cancer\/via-biliar?start=1"},{"key":"4397_CR7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","volume":"71","author":"P Bertuccio","year":"2019","unstructured":"Bertuccio P, Malvezzi M, Carioli G, Hashim D, Boffetta P, El-Serag HB, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71:104\u201314. https:\/\/doi.org\/10.1016\/j.jhep.2019.03.013.","journal-title":"J Hepatol"},{"key":"4397_CR8","doi-asserted-by":"publisher","unstructured":"Gaete Letelier DI, Saur\u00e9 Maritano A, Mandiola Bunster C. Actualizaci\u00f3n del manejo cl\u00ednico del Colangiocarcinoma Intrahep\u00e1tico P arte I: Epidemiolog\u00eda, Clasificaci\u00f3n y Diagn\u00f3stico. Rev Cir (Mex). 2025; 77. Available from: https:\/\/doi.org\/10.35687\/s2452-454920250012424","DOI":"10.35687\/s2452-454920250012424"},{"key":"4397_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.37352\/2023461.3","volume":"46","author":"A P\u00e9rez Ram\u00edrez","year":"2023","unstructured":"P\u00e9rez Ram\u00edrez A, Ruz Zafra P, P\u00e9rez Estrada C, S\u00e1nchez Torrijos Y. Cholangiocarcinoma: a current literature review. Rev Andal Patol Dig. 2023;46:26\u201337. https:\/\/doi.org\/10.37352\/2023461.3.","journal-title":"Rev Andal Patol Dig"},{"key":"4397_CR10","unstructured":"Laguna A, Liza LN, Dur\u00e1n E, Concepci\u00f3n JD, L\u00f3pez J, Retortillo JAP. Diagn\u00f3stico por im\u00e1genes en el colangiocarcinoma. 2018;"},{"key":"4397_CR11","doi-asserted-by":"publisher","DOI":"10.22516\/25007440.188","volume":"33","author":"CA Guerrero Bermudez","year":"2018","unstructured":"Guerrero Bermudez CA, V\u00e9lez Mar\u00edn M, Restrepo Guti\u00e9rrez JC. Colangiocarcinoma en pacientes con colangitis esclerosante primaria. Rev Colomb Gastroenterol. 2018;33:285. https:\/\/doi.org\/10.22516\/25007440.188.","journal-title":"Rev Colomb Gastroenterol"},{"key":"4397_CR12","unstructured":"N N. Biomarkers and Management of Cholangiocarcinoma: Unveiling New Horizons for Precision Therapy. 2025; Available from: https:\/\/europepmc.org\/article\/MED\/40227772"},{"key":"4397_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102649","volume":"122","author":"A Stenzinger","year":"2024","unstructured":"Stenzinger A, Vogel A, Lehmann U, Lamarca A, Hofman P, Terracciano L, et al. Molecular profiling in cholangiocarcinoma: a practical guide to next-g eneration sequencing. Cancer Treat Rev. 2024;122:102649. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102649.","journal-title":"Cancer Treat Rev"},{"key":"4397_CR14","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/14737167.2022.2078310","volume":"22","author":"E de Alava","year":"2022","unstructured":"de Alava E, Pareja MJ, Carcedo D, Arrabal N, Garc\u00eda J-F, Bernab\u00e9-Caro R. Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspective. Expert Rev Pharmacoecon Outcomes Res. 2022;22:1033\u201342. https:\/\/doi.org\/10.1080\/14737167.2022.2078310.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"4397_CR15","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","volume":"31","author":"F Mosele","year":"2020","unstructured":"Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31:1491\u2013505. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.014.","journal-title":"Ann Oncol"},{"key":"4397_CR16","doi-asserted-by":"publisher","DOI":"10.1200\/GO.21.00046","author":"WA Mantilla","year":"2021","unstructured":"Mantilla WA, Sanabria-Salas MC, Baldion AM, Sua LF, Gonzalez DM, Lema M. NGS in lung, breast, and unknown primary cancer in Colombia: a multidisciplinary consensus on challenges and opportunities. JCO Glob Oncol. 2021. https:\/\/doi.org\/10.1200\/GO.21.00046.","journal-title":"JCO Glob Oncol"},{"key":"4397_CR17","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","volume":"147","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147:573\u20137.","journal-title":"Ann Intern Med"},{"key":"4397_CR18","doi-asserted-by":"crossref","unstructured":"Vera R, Ibarrola-de-Andr\u00e9s C, Adeva J, P\u00e9rez-Rojas J, Garc\u00eda-Alfonso P, Rodr\u00edguez-Gil Y, et al. Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer. Clin & Transl Oncol Off Publ Fed Spanish Oncol Soc Natl Cancer Inst Mex. 2022;24:2107\u20142119. Available from: https:\/\/europepmc.org\/articles\/PMC9522813","DOI":"10.1007\/s12094-022-02873-0"},{"key":"4397_CR19","doi-asserted-by":"crossref","unstructured":"Rimassa, L Khan, S Groot Koerkamp, B Roessler, S Andersen, JB Raggi , C Lleo, A Nault, JC Calderaro Gabbi , C Kather, JN Banales, JM Bargellini, I Morement, H Krawczyk, M Farazi, PA Carpino, G Avila, MA Saborowski , A Cardinale, V Braconi , C Macias R. Mapping the landscape of biliary tract cancer in Europe: challenges and controversies. 2025; Available from: https:\/\/europepmc.org\/article\/MED\/40093398","DOI":"10.1016\/j.lanepe.2024.101171"},{"key":"4397_CR20","doi-asserted-by":"crossref","unstructured":"Rimassa L, Lamarca A, O\u2019Kane GM, Edeline J, McNamara MG, Vogel A, et al. New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe. Lancet Reg Heal Eur [Internet]. 2025;50:101170. Available from: https:\/\/europepmc.org\/articles\/PMC11910789","DOI":"10.1016\/j.lanepe.2024.101170"},{"key":"4397_CR21","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","volume":"76","author":"L Izquierdo-Sanchez","year":"2022","unstructured":"Izquierdo-Sanchez L, Lamarca A, La Casta A, Buettner S, Utpatel K, Kl\u00fcmpen H-J, et al. Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J Hepatol. 2022;76:1109\u201321. https:\/\/doi.org\/10.1016\/j.jhep.2021.12.010.","journal-title":"J Hepatol"},{"key":"4397_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2022.11.006","volume":"179","author":"GS Roth","year":"2023","unstructured":"Roth GS, Neuzillet C, Sarabi M, Edeline J, Malka D, Li\u00e8vre A. Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine\u202f? Eur J Cancer. 2023;179:1\u201314. https:\/\/doi.org\/10.1016\/j.ejca.2022.11.006.","journal-title":"Eur J Cancer"},{"key":"4397_CR23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/14737159.2025.2518145","volume":"25","author":"F Castet","year":"2025","unstructured":"Castet F, Salcedo MT, Nuciforo P, Aguilar S, Vivancos A. Best practices in sample management and molecular profiling of cholang iocarcinoma: a practical guide. Expert Rev Mol Diagn. 2025;25:479\u201394. https:\/\/doi.org\/10.1080\/14737159.2025.2518145.","journal-title":"Expert Rev Mol Diagn"},{"key":"4397_CR24","unstructured":"A Descriptive, Multicentre, Observational Epidemiological Study on Digestive Tumours. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06711211"},{"key":"4397_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11523-025-01132-w","volume":"20","author":"S Camera","year":"2025","unstructured":"Camera S, Rossari F, Foti S, Vitiello F, Persano M, Lo PF, et al. HER2 pathway in biliary tract cancer: a snapshot of the\u00a0current understanding and future directions. Target Oncol. 2025;20:269\u201380.","journal-title":"Target Oncol"},{"key":"4397_CR26","doi-asserted-by":"publisher","first-page":"e6827","DOI":"10.1002\/cam4.6827","volume":"13","author":"S Zazo","year":"2024","unstructured":"Zazo S, P\u00e9rez-Buira S, Carvajal N, Plaza-S\u00e1nchez J, Manso R, P\u00e9rez-Gonz\u00e1lez N, et al. Actionable mutational profiling in solid tumors using hybrid-capture-based next-generation sequencing in a real-world setting in Spain. Cancer Med. 2024;13:e6827.","journal-title":"Cancer Med"},{"key":"4397_CR27","doi-asserted-by":"crossref","unstructured":"Stenzinger A Normanno N LARLBFTPVAHA. From barriers to solutions: an expert-based algorithm for cholangiocarcinoma and other biliary tract cancers testing in the Era of precision oncology. 2025; Available from: https:\/\/europepmc.org\/article\/MED\/40574643","DOI":"10.1080\/14737159.2025.2521538"},{"key":"4397_CR28","doi-asserted-by":"publisher","first-page":"e2200546","DOI":"10.1200\/PO.22.00546","volume":"7","author":"E Arriola","year":"2023","unstructured":"Arriola E, Bernab\u00e9 R, Campelo RG, Biscuola M, Enguita AB, L\u00f3pez-R\u00edos F, et al. Cost-effectiveness of next-generation sequencing versus single-gene testing for the molecular diagnosis of patients with metastatic non-small-cell lung cancer from the perspective of spanish reference centers. JCO Precis Oncol. 2023;7:e2200546.","journal-title":"JCO Precis Oncol"},{"key":"4397_CR29","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S2468-1253(21)00171-0","volume":"6","author":"AE Kam","year":"2021","unstructured":"Kam AE, Masood A, Shroff RT. Current and emerging therapies for advanced biliary tract cancers. Lancet Gastroenterol Hepatol. 2021;6:956\u201369.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4397_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104224","volume":"194","author":"M Fassan","year":"2024","unstructured":"Fassan M, Angerilli V, Normanno N, Pruneri G, Marchetti A, Grillo F, et al. Practical guidelines for molecular testing of cholangiocarcinoma in clinical practice: Italian experts\u2019 position paper. Crit Rev Oncol Hematol. 2024;194:104224.","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04397-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04397-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04397-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:02:19Z","timestamp":1792803739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04397-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["4397"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04397-3","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"29 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jorge Adeva Alfonso has received honoraria for lectures, advisory roles, travel, and accommodations from Servier, Incyte, Taiho, AstraZeneca, MSD and Jazz Pharmaceuticals. Alfredo Carrato declares no conflicts of interest related to this work. Teresa Macarulla has received consulting fees from Ability Pharmaceuticals, Arcus Bioscience Inc, AstraZeneca, Basilea Pharma, Baxter, BioLineRX Ltd, Celgene, Eisai, Incyte, Ipsen Bioscience Inc; honoraria from BioNTech, Da\u00efchi, Esteve, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Eli Lilly, and Novartis; travel support from AstraZeneca, Incyte, Eli Lilly, Merck Sharp & Dohme, Roche, Sanofi, and Servier; and research support from Merck Sharp & Dohme, Novocure, QED Therapeutics, Roche, Sanofi Aventis, Servier, and Zymeworks (the institution receives research support from AbbVie, Ability Pharmaceuticals, Agios Pharmaceuticals, Amgen, Aslan Pharmaceuticals, AstraZeneca, Basilea Pharmaceutica International, Bayer, BeiGene, BioKeralty Research Institute, BioLineRx, Blueprint Medicines, Boston Biomedical, Bristol Myers Squibb, Cantargia, Celgene, Eisai, Erytech Pharma, FibroGen, Halozyme, Incyte, Ipsen, Eli Lilly, Loxo Oncology, MedImmune, Merck Sharp & Dohme, Nelum, Novartis, Novocure, OncoMed Pharmaceuticals, QED Therapeutics).","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}